Pulmonology

Dr. Au spoke of how the new data provides an opportunity to think about how lifestyle intervention focused on weight and moderate exercise can actually have meaningful impacts on patients with COPD.

This model was responsible for correctly identifying 73% of patients with pulmonary arterial hypertension 6 months prior to a confirmed diagnosis.

Dr. Holly Keir cites "massive changes" in beta diversity following ICS withdrawals in patients with moderate to very severe COPD.

Dr. Lugogo explains how the ProAir Digihaler was used to accurately monitor SABA use in patients with asthma -many of whom were overusing their medication- which could allow clinicians to make appropriate changes to treatment.

The new study provides insights into the physiological factors for greater AtoOxy efficacy and can be referenced when identifying patients who are most suited for the therapy.

Elliot Israel, MD, and Juan Carlos Cardet, MD, MPH, join Lungcast to discuss their latest research into addressing Black and Latinx asthma outcome disparities.

Patients with a positive family history of OSA tended to be female with more severe OSA based on a higher AHI.

Obstructive sleep apnea has previously been associated with pulmonary hypertension in literature, with investigators citing a “complex and bidirectional relationship” between the 2 conditions.

Investigators from this ATS session suggested THN therapy could be used to treat OSA, believing in to be “a simpler approach than incumbent technology with no sensor and an easier, proximal electrode implantation”.

Dr. Rizzo sits down with HCPLive to discuss the impact of air pollution and allergies on pulmonary health, as well as new research on pulmonary arterial hypertension.

Research has indicated that a fixed-dose combination of albuterol and budesonide could better reduce the risk of severe asthma exacerbation when compared to albuterol alone.

Patients treated twice-daily with an 18 mg dose of BI 1015550 experienced prevention of decreased lung function regardless of any background antifibrotic agents.

Previously, the US Preventive Services Task Force reviewed screening evidence for COPD in 2016 and issued a D recommendation against screening in asymptomatic adults.

Stephanie Lovinsky-Desir, MD, MS, discusses key findings from the 2022 ALA State of the Air Report.

Mehdi Mirsaeidi, MD, MPH, Director of the ILD and Sarcoidosis Program at the Jacksonville College of Medicine, joins Lungcast to review the rare disease for Sarcoid Awareness Month.

The 2022 State of the Air report from the American Lung Association highlights growing disparities in coastal-based ozone and particle pollution, amid wildfires and shifts in regulatory policies.

Dr. Stephanie Lovinsky-Desir speaks on the staggering new data from the 23rd annual "State of the Air" report by the American Lung Association.

After adjustment for age and sex, data show the reduction in mortality rates in the patients receiving dialysis was greater than the general population.

Data show omecamtiv mecarbil added to background therapy had no significant improvement regarding exercise capacity.

In a population aged 70 years and older, a remote history of VT was associated with an increased risk of VT independent of other factors.

Interstitial lung disease expert explains the importance of educating patients with autoimmune disease.

Overall tobacco use declined among adults since 2019—but many from varying sociodemographic backgrounds are still reporting high use.

Dr. Lee highlights the process of identifying CTEPH and the patient population, as well as the available treatments for the condition.

ChristianaCare’s Gene Editing Institute experts join the podcast to discuss the latest developments in gene editing.

The inhaler is approved for 2 strengths, 160/4.5 mcg/actuation and 80/4.5 mcg/actuation.

In an interview, lead investigator and expert Dr. Martin Kolb discusses his new phase 2b HZN-825 trial and what it's like treating the rare disease.

The reductions were seen as early as week 2 and was sustained throughout the 52 week study.

Dr. Zein speaks of the relationship between eosinophil count and COVID-19 illness and mortality, especially as it related to inhaled corticosteroid use.